{"id":"W2948365327","doi":"10.1200/jco.2019.37.18_suppl.lba3","title":"ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Anthracycline; Population; Neutropenia; Dexrazoxane; Doxorubicin; Randomization; Placebo; Phases of clinical research; Urology; Randomized controlled trial; Oncology; Surgery; Gastroenterology; Toxicity; Chemotherapy; Cancer; Breast cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002030027,0.002289199,0.002757099,0.0005760448,0.0004601089,0.001106538,0.001269239,0.001889169,0.01137613],"category_scores_gemma":[0.001924647,0.0009739927,0.00113171,0.0004433288,0.001495336,0.001408822,0.0006974483,0.003308868,0.001583559],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005858101,"about_ca_system_score_gemma":0.001379516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005453546,"about_ca_topic_score_gemma":0.001515117,"domain_scores_codex":[0.999378,0.0003783573,0.00002858207,0.00008868802,0.00004327902,0.00008307341],"domain_scores_gemma":[0.9989545,0.0002991548,0.0002531387,0.00007776674,0.00005287031,0.0003624426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9841112,0.004701318,0.0001780289,0.0003531541,0.0001308714,0.00001904645,0.00002638108,0.0002179846,0.002506042,0.000135078,0.0007203433,0.006900447],"study_design_scores_gemma":[0.9626512,0.03600366,0.0003166569,0.00001115474,0.00008129582,0.00001391171,0.000008105697,0.000192641,0.0002525078,0.00007676189,0.0003865363,0.000005647248],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.9625285,0.003788272,0.002187202,0.001649825,0.00125582,0.0181601,0.004572953,0.0007289621,0.005128315],"genre_scores_gemma":[0.9562368,0.003427329,0.004215566,0.002385829,0.001145728,0.02109759,0.003093632,0.0001113709,0.008286247],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01137613,"threshold_uncertainty_score":0.03805691,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06501265917635984,"score_gpt":0.4374574538321799,"score_spread":0.3724447946558201,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}